Related Experiment Video
Updated: Jun 28, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
Published on: April 19, 2024
Bacillus Calmette-Guérin Therapy: Optimizing Outcomes amid Challenges
Tutku E Tazegul1, Michael O'Donnell1, Helen Y Hougen1
1Department of Urology, University of Iowa, 200 Hawkins Drive, 3RCP, Iowa City, IA 52242, USA.
None:
Bacillus Calmette-Guérin (BCG) remains the cornerstone adjuvant therapy for intermediate-risk and high-risk non--muscle invasive bladder cancer, yet its clinical utility is increasingly challenged by supply shortages, treatment intolerance, and variable oncologic response. This article summarizes the immunologic basis, efficacy, and limitations of BCG, examines evidence for alternative administration strategies, evaluates combination and biomarker-based approaches to optimize patient selection, and outlines emerging therapies for BCG-unresponsive disease. Practical, evidence-driven recommendations are provided to guide contemporary management during periods of constrained supply and evolving therapeutic landscapes.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Pharmaceutical Poisoning: Treatment Strategies
Antimicrobial Effectiveness
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
